SRC and familial pancreatic carcinoma: In pancreatic cancer cells, CSK inhibition using the inhibitor ASN2324598 substantially decreases Y527 phosphorylation in Src, resulting in increased proliferation and activation of pro-oncogenic pathways, such as MAPK/MEK, and pro-angiogenic growth factors, like VEGF (Pema et al., 2005).